findmyKOL
Clinical trialNCT06957431RecruitingPhase 1Interventional

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

SponsorWashington University School of MedicineEnrollment18Adipocytic SarcomaAdvanced LeiomyosarcomaAdvanced Liposarcoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Washington University School of Medicine

    St Louis, Missouri, United States

    Angela Hirbe, M.D., Ph.D.Brian Van Tine, M.D., Ph.D.Chongliang (Jason) Luo, Ph.D.Mia C Weiss, M.D.Sasha Haarberg, PharmD, BCOP
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

EribulinZanzalintinib
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
22 Oct 2025
Primary completion
31 May 2031
Completion
30 Apr 2036
Last update posted
3 Jun 2026
Registered enrollment
18
Registry id
NCT06957431
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.